© 2021 MJH Life Sciences™ and Clinical Care Targeted Communications, LLC. All rights reserved.
December 2017
Perspectives of a Lipidologist: LDL Cholesterol Testing, PCSK9 Inhibitors
December 26, 2017
Article
Evidence-Based Diabetes Management
The CVD-Real Trial: What Can Real-World Evidence Tell Us About Primary Prevention?
December 19, 2017
Article
Evidence-Based Diabetes Management
An interview with one of the authors of a large observational study that has seen findings consistent with recent cardiovascular outcomes trials in SGLT2 inhibitors.
As Trials Report Cardiovascular Outcomes Data, What About Microvascular Results?
December 18, 2017
Article
Evidence-Based Diabetes Management
Evidence is more robust on kidney function but not sufficient to make drug decisions, one expert said. A whole separate trial, called CREDENCE, is examining renal function in patients taking canagliflozin.
Moving Pharma Contracting Into the Era of Accountability
December 14, 2017
Article
Evidence-Based Diabetes Management
A chief medical officer for a major payer outlines the challenges making sure that certain high-cost therapies are directed to the patients who need them.
For Those With Diabetes and CV Risk, Personalized Care Matters
December 14, 2017
Article
Evidence-Based Diabetes Management
From the Editor in Chief
Eldrin F. Lewis, MD, MPH, on Heart Failure's Place in Diabetes Drug Trials, and the Promise of SGLT2s in Prevention
December 13, 2017
Article
Evidence-Based Diabetes Management
The payment reform movement has changed the thinking about what can be done for patients with diabetes and heart failure, for the good of patients.
“Sprint to Zero“: A Strategy to Address High Rates of Nontraumatic Amputations in Minority Communities
December 12, 2017
Article
Evidence-Based Diabetes Management
CMS can take steps to raise awareness, including a specific quality measure, to ensure that testing occurs prior to nontraumatic amputation.